Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 45, 102404
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- Early highly aggressive MS successfully treated by hematopoietic stem cell transplantationMultiple Sclerosis Journal, 2008
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007
- Costs and quality of life in multiple sclerosisNeurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- The Concept of Clinically Meaningful Difference in Health-Related Quality of Life ResearchPharmacoEconomics, 2000
- Multiple SclerosisNew England Journal of Medicine, 2000
- Rating neurologic impairment in multiple sclerosisNeurology, 1983